Ideaya Biosciences (IDYA) PT Raised to $65 at Truist Securities

Ideaya Biosciences (IDYA) PT Raised to $52 at Mizuho, 'we recommend being opportunistic'

Mizuho analyst Graig Suvannavejh raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $52.00 (from $46.00) while maintaining a Outperform rating.

The analyst comments "Following up on Quick Take comments earlier today (LINK) on positive P2/3 data for darovasertib/daro (a protein kinase C/PKC... More

Ideaya Biosciences (IDYA) PT Raised to $35 at Goldman Sachs

Goldman Sachs analyst Corinne Jenkins raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $35.00 (from $31.00) while maintaining a Neutral rating.

The analyst comments "IDYA hosted a conference call to discuss topline Ph2/3 darovasertib plus crizotinib data in metastatic uveal melanoma (mUM),... More

Ideaya Biosciences (IDYA) PT Raised to $58 at Wedbush

Wedbush analyst Robert Driscoll raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $58.00 (from $52.00) while maintaining a Outperform rating.

IDEAYA and Servier report positive phase 2/3 trial results for uveal melanoma

IDEAYA Biosciences Inc. (NASDAQ: IDYA) and Servier announced that their Phase 2/3 OptimUM-02 trial met its primary endpoint, showing statistically significant improvement in progression-free survival for patients with first-line HLA-A*02:01-negative metastatic uveal melanoma.

The trial evaluated darovasertib in combination with crizotinib against investigator choice of therapy in 313 patients. The combination... More

IDEAYA to report uveal melanoma trial results April 13

IDEAYA Biosciences Inc. (NASDAQ: IDYA) will announce topline results from its Phase 2/3 OptimUM-02 trial on April 13, 2026, the company said April 10.

The registrational trial evaluates darovasertib combined with crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma. IDEAYA is... More